Cargando...
Circulating Integrin Alpha4/Beta7+ Lymphocytes Targeted by Vedolizumab Have a Pro-Inflammatory Phenotype
Integrin alpha4/beta7 on circulating lymphocytes identifies them as gut-tropic, and can be targeted by the humanized antibody vedolizumab to treat inflammatory bowel disease (IBD). We found lymphocytes expressing alpha4/beta7 were significantly more responsive to the pro-inflammatory cytokines IL-6,...
Gardado en:
| Publicado en: | Clin Immunol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6257989/ https://ncbi.nlm.nih.gov/pubmed/29842945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2018.05.006 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|